Sign in Subscribe
Biological products industry

Chiron Corp. Grants Nonexclusive License to InterMune for HCV Therapeutics

Strategic Insights

— 1 min read

Chiron Corp. has granted a nonexclusive license to InterMune, Inc. for the research, development, and commercialization of therapeutics against hepatitis C virus (HCV) drug targets, expanding the company's efforts to combat the disease. This agreement builds on Chiron's licensing policy, which aims to provide flexibility to licensees by confirming the availability of no up-front or annual payments. The company has already granted similar licenses to several organizations, including Boehringer-Ingelheim International, GmbH, Gilead Sciences, Pfizer, Rigel Pharmaceuticals, and Vertex Pharmaceuticals. Chiron's HCV technology is being developed and commercialized through various partnerships and internal programs, including the Procleix System, which screens whole blood donations for HCV, HIV-1, and hepatitis B.

Key Takeaways:

  • Chiron Corp. granted a nonexclusive license to InterMune, Inc. for HCV therapeutics, expanding its licensing policy to combat the disease.
  • The agreement confirms no up-front or annual payments, providing flexibility to licensees.
  • Chiron has granted similar licenses to organizations including Boehringer-Ingelheim International, GmbH, Gilead Sciences, Pfizer, Rigel Pharmaceuticals, and Vertex Pharmaceuticals.
  • The company's HCV technology is being developed and commercialized through partnerships and internal programs, including the Procleix System.
  • Chiron's Procleix System screens whole blood donations for HCV, HIV-1, and hepatitis B.
  • The company is conducting two phase I trials for HCV vaccine candidates and has a small-molecule therapeutic in preclinical testing.

Statistics:

  • 2004: Chiron granted nonexclusive licenses to its HCV technology to various organizations.
  • 2003: Chiron granted nonexclusive licenses to its HCV technology to six organizations; Boehringer-Ingelheim International, GmbH, Gilead Sciences, Pfizer, Rigel Pharmaceuticals, and Vertex Pharmaceuticals.
  • Multiple licenses: Chiron has granted nonexclusive licenses to its HCV technology to several organizations, including InterMune, Inc. and Prosetta Corp.

Sources:

  • NewsRx.com & NewsRx.net (2004 OCT 11)
  • Health & Medicine Week editors (2004)
  • Chiron Corp.
  • InterMune, Inc.
  • Gen-Probe Inc.

Read more